Boehringer Ingelheim invests US$130 mn (€120 mn) to expand its production site in Greece.
The expansion project will result in a boosted manufacturing capacity for both new and established medications, with a primary focus on addressing diseases in key areas such as cardio-renal-metabolic (CRM) disorders, mental health conditions, and pulmonary fibrosis.
The investment in expansion aims to make cutting-edge therapies accessible to a growing global patient population. This expansion will enlarge the manufacturing capabilities within the region.
The expansion project is set to generate 110 additional jobs and enhance the export of pharmaceuticals from Greece, with a specific focus on Jardiance®. Jardiance is recognised for its effectiveness in treating diabetes, heart failure, and chronic kidney disease.
In addition to expanding production for Jardiance, it also plans to augment capacity for specific drugs in late-stage development.
The expansion initiative will generate 110 new job opportunities.
Name Boehringer Ingelheim
Budget US$130 million (€120 mn)